A new prognostic strategy for gastric carcinoma: Albumin level and metastatic lymph node ratio

Minerva Chirurgica

Volumn 69, Issue 3, 2014, Pages 147-153

  Isik, A ^a   Okan, I ^b   Firat, D ^a   Yilmaz, B ^c   Akcakaya, A ^d   Sahin, M ^b  

^a ERZINCAN UNIVERSITY   (Turkey)

^b GAZIOSMANPASA UNIVERSITY   (Turkey)

^c DENIZLI STATE HOSPITAL   (Turkey)

^d Bezmialem University   (Turkey)

Author keywords

Albumins; Lymph nodes; Stomach neoplasms

Indexed keywords

ALBUMINOID; TUMOR MARKER;

AGED; BLOOD; CANCER STAGING; CARCINOMA; FEMALE; FOLLOW UP; GASTRECTOMY; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SECONDARY; STOMACH NEOPLASMS; TREATMENT OUTCOME;

AGED; ALBUMINS; CARCINOMA; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84925555622     PISSN: 00264733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Turkish Association For Cancer Research and Control [Homepage]. [cited 2014 May 8]. Available from: http://www.turkkanser.org.tr
3. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
4. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996-2004.
5. Goldwasser P, Felman J. Association of serum albumin and mortality risk. J Clin Epidemiol 1997;50:693-703.
6. Okamura T, Hayakawa T, Kadowaki T, Kita Y, Okayama A, Elliot P et al.; NIPPON DATA80 Research Group. A combination of serum low albumin and above-average cholesterol level was associated with excess mortality. J Clin Epidemiol 2004;57:1188-95.
7. Onate-Ocana LF, Aiello-Crocifoglio V, Gallardo-Rincon D, Herrera-Goepfert R, Brom-Valladares R, Carrillo JF et al. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol 2007;14:381-9.
8. Onate-Ocana LF, Becker M, Carrillo JF. Selection of best candidates for multiorgan resection among patients with T4 gastric carcinoma. J Surg Oncol 2008;98:336-42.
9. Orditura M, De Vita F, Muto P, Vitiello F, Murino P, Lieto E et al. Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot study. Arch Surg 2010;145:233-8.
10. Farrugia A. Albumin usage in clinical medicine: tradition or therapeutic? Transfus Med Rev 2010;24:53-63.
11. McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 2007;22:881-6.
12. Neal CP, Mann CD, Sutton CD, Garcea G, Ong SL, Steward WP et al. Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastases. Eur J Cancer 2009;45:56-64.
13. Crumley AB, Stuart RC, McKernan M, McMillan DC. Is hypoalbuminemia an independent prognostic factor in patients with gastric cancer? World J Surg 2010;34:2393-8.
14. Crumley AB, Stuart RC, McKernan M, Going JJ, Shearer CJ, McMillan DC. Comparison of pretreatment clinical prognostic factors in patients with gastrooesophagealcancer and proposal of a new staging system. J Gastrointest Surg 2010;14:781-7.
15. Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC. Evaluation of an inflammation-based prognostic score in patients with inoperable gastrooesophageal cancer. Br J Cancer 2006;;94:637-41.
16. Oñate-Ocaña LF, Milán-Revollo G, Aiello-Crocifoglio V, Carrillo JF, Gallardo-Rincón D, Brom-Valladares R et al. Treatment of the adenocarcinoma of the esophagogastric junction at a single institution in Mexico. Ann Surg Oncol 2007;14:1439-48.
17. Lien YC, Hsieh CC, Wu YC, Hsu HS, Hsu WH, Wang LS et al. Preoperative serum albumin level is a prognostic indicator for adenocarcinoma of the gastriccardia. J Gastrointest Surg. 2004;8:1041-8.
18. Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 2007;18:886-91.
19. Alici S, Kaya S, Izmirli M, Tuncer I, Doǧan E, Ozbek H, Sayarlioglu H. Analysis of survival factors in patients with advanced-stage gastric adenocarcinoma. Med Sei Monit 2006;12:221-9-
20. Ke B, Uu N, Liang H, Zhang RP, Wang XJ, Wu LL. Prognosis analysis of 310 patients with pathological stage pN3 gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi 2013;16:543-6.
21. Lu J, Huang CM, Zheng CH, Li P, Xie JW, Wang JB et al. Consideration of tumor size improves the accuracy of TNM predictions in patients with gastric cancer after curative gastrectomy. Surg Oncol 2013;17:58-3.
22. Medina-Franco H, Cabrera-Mendoza F, Almaguer-Rosales S, Guillen F, Suarez-Bobadilla YL, Sanchez-Ramon A. Lymph node ratio as a predictor of survival in gastric carcinoma. Am Surg 2013;79:284-9.